We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Saliva Test More Accurately Indicates Severity of Recurrent Respiratory Infections in Children

By LabMedica International staff writers
Posted on 09 Aug 2024

Approximately 10-15% of children experience recurrent respiratory infections, prompting hospital visits where blood tests are commonly performed to check for antibody deficiencies. More...

Yet, these tests often fail to provide helpful insights. There is a pressing need for alternative methods that better assess the severity of the condition, which would aid in determining when increased care or antibiotic treatment is necessary. Now, new research reveals that saliva testing might offer a more accurate reflection of the severity of recurrent respiratory infections in children compared to traditional blood tests. If saliva contains too few broadly protective antibodies, there is a higher likelihood of pneumonia episodes for the children.

The collaborative study by researchers at Radboudumc Amalia Children's Hospital (Nijmegen, Netherlands) and UMC Utrecht Wilhelmina Children's Hospital (Utrecht, Netherlands) involving 100 children with recurrent respiratory infections found that saliva tests are better indicators of disease severity than blood tests. The study demonstrated no significant correlation between blood antibodies and the extent of infection. However, saliva revealed the presence of broadly protective antibodies effective against various pathogens. Children with lower levels of these antibodies in their saliva experienced more severe infections. Interestingly, these antibodies are common in the airways of healthy individuals, including siblings and parents of affected children and their caregivers. A high level of these antibodies in saliva correlates with a strong defense against respiratory infections. Remarkably, these antibodies were even capable of binding to the SARS-CoV-2 virus in samples collected before the pandemic. Despite their abundance in saliva, these antibodies are rarely detected in blood.

The research also explored the balance of healthy and potentially harmful bacteria within the airway's mucous membranes, or microbiome. It identified a specific bacterium, Haemophilus influenzae, on the nasopharyngeal mucosa that is closely linked to the severity of respiratory infections. While this bacterium is also found in healthy airways, its high abundance is associated with increased illness frequency during the winter months, and it has been previously associated with pneumonia episodes. The findings, published in the European Respiratory Journal, highlight the potential of saliva and nasopharyngeal mucosal measurements as valuable tools in evaluating children with recurrent respiratory infections. Saliva testing not only offers new avenues for treatment but also sheds light on preventive measures; for instance, the flu vaccine has been shown to boost the level of protective antibodies in the saliva of healthy caregivers. Further research is underway to explore the potential of these antibodies in treating respiratory infections more effectively in the future.

“This helps us assess the amount of care and medication children need and which antibiotic to use, as the current standard does not work optimally against Haemophilus influenzae,” said PhD student Mischa Koenen. “I expect the initial blood test to remain, but for follow-up appointments, a more child-friendly saliva and nasopharyngeal swab could be used as indicators of expected respiratory disease burden.”

Related Links:
Radboudumc Amalia Children's Hospital
UMC Utrecht Wilhelmina Children's Hospital


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Varicella Zoster Virus Assay
LIAISON VZV Assay Panel (IgG HT, IgM)
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.